Evidence map›Paper›PMID 42860452›Full record

ArticleZeitschrift fur Rheumatologie2026

[Predictors of willingness for COVID-19 vaccination in patients with inflammatory rheumatic diseases at the beginning of the vaccination rollout].

Dana Delia, Ulf Müller-Ladner, Jörn Pons-Kühnemann, Matthias Broll, Björn Bühring, Eike Domgörgen, Andreas Dormann, Rebecca Hasseli, Farid I Kandil, Ilka Kraeft and 18 more

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Dana DeliaMedizinische Klinik II, Klinik für internistische Rheumatologie, Cellitinnen-Krankenhaus St. Josef, Bergstr. 6-12, 42105, Wuppertal, Deutschland. dana.delia@cellitinnen.de.ORCID https://orcid.org/0009-0002-3854-4348
Ulf Müller-LadnerCampus Kerckhoff, Abteilung für Rheumatologie und Klinische Immunologie, Justus-Liebig, Universität Gießen, Bad Nauheim, Deutschland.
Jörn Pons-KühnemannInstitut für Medizinische Informatik, Justus-Liebig-Universität Gießen, Gießen, Deutschland.
Matthias BrollPraxisklinik Mittelhessen, Wetzlar, Deutschland.
Björn BühringMedizinische Klinik II, Klinik für internistische Rheumatologie, Cellitinnen-Krankenhaus St. Josef, Bergstr. 6-12, 42105, Wuppertal, Deutschland.
Eike DomgörgenAllgemeinmedizinische Praxis Habbelrath, Frechen, Deutschland.
Andreas DormannRheumazentrum Ratingen, Ratingen, Deutschland.
Rebecca HasseliSektion Rheumatologie und Klinische Immunologie, Universitätsklinikum Münster, Münster, Deutschland.
Farid I KandilInstitut für Biometrie, Informatik und Epidemiologie (IMBIE), Universitätsklinikum Bonn, Bonn, Deutschland.
Ilka KraeftHausarztpraxis Burgstraße, Dormagen, Deutschland.
Andreas KrauseKlinik für Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus, Berlin, Deutschland.
Hanns-Martin LorenzSektion Rheumatologie, Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
Nicole MorenaMedizinisches Versorgungszentrum Hochsauerland, Praxis für Rheumatologie, Hüsten, Deutschland.
Filiz ÖzdenFacharztpraxis für Rheumatologie und Osteologie Nienburg, Nienburg, Deutschland.
Alexander PfeilRheumazentrum (G-BA-Kriterien) sowie Sektion Rheumatologie und Osteologie, Klinik für Innere Medizin III, Universitätsklinikum Jena, Jena, Deutschland.
Jutta G RichterKlinik für Rheumatologie, Medizinische Fakultät, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland.
Jasemine SaechGemeinschaftspraxis Rheumatologie-Centrum Leverkusen, Leverkusen, Deutschland.
Thomas SchneidereitRheumapraxis Wuppertal, Wuppertal, Deutschland.
Andreas SchlesingerLungenklinik Köln Nord, Cellitinnen-Krankenhaus St. Marien, Köln, Deutschland.
Christof SpeckerKlinik für Rheumatologie und Klinische Immunologie, Evangelisches Krankenhaus Essen Mitte, Essen, Deutschland.
Kathrin Storck-MüllerKompetenzzentrum für Rheumatologie Bad Endbach, Rheumazentrum Mittelhessen, Bad Endbach, Deutschland.
Johannes StrunkKlinik für Rheumatologie, Krankenhaus Porz am Rhein, Köln, Deutschland.
Konstantinos TriantafylliasSchwerpunkt Rheumatologie und klinische Immunologie, Johannes Gutenberg Universitätsmedizin Mainz, Mainz, Deutschland.
Daniel VagedesMVZ Klinikum Straubing, Straubing, Deutschland.
Katharina VesperGemeinschaftspraxis Bergstraße, Wuppertal, Deutschland.
Siegfried WassenbergRheumazentrum Ratingen, Ratingen, Deutschland.
Sami ZeglamRheumapraxis Bad Neuenahr-Ahrweiler, Bad Neuenahr-Ahrweiler, Deutschland.
Tim SchmeiserPraxis Rheumatologie im Veedel, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn January 2021 the coronavirus disease 2019 (COVID-19) was coupled to high case numbers and mortality worldwide and in Germany. The start of the vaccination campaign was initially characterized by limited availability and uncertainty but rapidly gained momentum. Patients with inflammatory rheumatic diseases (IRD) were prioritized at an early stage due to the high risk for a severe disease trajectory. In this group vaccination proved to be effective and greatly reduced the risk of a severe course. The aim of the study was to ascertain the willingness for vaccination and the influencing factors in patients with IRD in order to optimize vaccination strategies and to reach vulnerable groups more easily.

methodsBetween January and April 2021 a nationwide survey was carried out in Germany among N= 3661 patients with IRD and N=381 control patients with other chronic internal diseases. The questionnaire covered willingness to undergo vaccination against COVID-19 and demographic and disease-related variables. For the analysis, "willing to be vaccinated" and "already vaccinated" were pooled ("vaccination willingness") and compared the unwilling. The statistical evaluation was carried out using χ2-tests, odds ratio (OR) analyses and logistic regression to identify independent influencing factors.

resultsThe proportions of those willing to be vaccinated were comparable in both groups with 90% very high (IRD 89.2% and control group 93.9%). They continually increased in both groups during the observational period and with increasing age. Another strong predictor was a previously carried out simultaneous vaccination for influenza, which was associated with a significantly higher willingness to be vaccinated in both groups.

conclusionThe willingness to be vaccinated against COVID-19 at the time of the vaccination rollout in Germany was high. For patients with IRD, it was predicted by age, previous vaccination against influenza and the timing of vaccination but not the subtype of IRD or the type of immunomodulatory medication. Young patients with IRD in particular should be systematically identified as a risk group with a low willingness to be vaccinated. For this patient group an intensified target group-specific vaccination counselling should be integrated into the clinical care, which specifically addresses suitable information channels for those affected.

Indexed as

AgeIRDIRD subtypeMedicationVaccination acceptance

Identifiers

PMID42860452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.